Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Mechanism of Lianhua Qingwen in Nasal Epithelial Cells of COVID-19 Patients
ChiCTR2200066842Phase 4Not yet recruiting
- Sponsor
- Hebei Yiling Hospital
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Yiling Hospital. Primary endpoint: Proportion of patients with major symptoms relieved. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200066842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066842.